Fisher & Paykel Healthcare Corporation Limited (NZSX:FPH, ASX:FPH) announced today that it has expanded its nasal mask offering with the introduction of the F&P Eson™ nasal mask for use in the treatment of obstructive sleep apnea (OSA).
“Every feature on the Eson has been designed to address the common complexities homecare providers and patients face when fitting, wearing and maintaining masks” commented Michael Daniell, Fisher & Paykel Healthcare’s Chief Executive Officer. “Our design team’s focus has been on simplicity and performance; the things that matter most to those that use the mask.”
The Eson’s three simple components: the RollFit™ Seal, ErgoFit Headgear and Easy Frame, work in harmony to deliver the comfort, seal and easy use for which Fisher & Paykel Healthcare masks are renowned. As the name suggests, the RollFit seal rolls back and forth on the bridge of the nose. In doing so, RollFit minimises pressure on the nasal bridge without the need for complicated T-piece adjustments.
The Eson is currently available in New Zealand, Australia and Canada and will soon be introduced to Europe, with the USA to follow on receipt of FDA clearance.
The Eson nasal mask complements the revolutionary F&P Pilairo nasal pillows mask which has recently been introduced into New Zealand, Australia, Canada and the United States with a very positive reception from customers and patients alike. In addition, the company’s Lady Zest™ Q nasal mask, which is designed specifically for women, is now available in all major markets.
“We have enjoyed a very encouraging initial response to these new premium masks and we expect that they will contribute significantly to our OSA product group revenue growth” concluded Mr Daniell.
Contact: Michael Daniell, MD/CEO on +64 9 5740161 or Tony Barclay, CFO on +64 9 574 0119. For more information about the company visit www.fphcare.com